We strive to make unique discoveries

As an affiliate of Servier our strategic focus is to apply our highly effective antibody platform and capabilities in the discovery and early development of highly differentiated antibody therapeutics, either as combination or stand-alone therapies supporting Servier’s R&D strategy.

Read more about Symphogen in our Annual Report 2019 (PDF)